Search

Your search keyword '"Tommy Fornander"' showing total 4 results
Start Over Author "Tommy Fornander" Journal annals of oncology
4 results on '"Tommy Fornander"'

1. LBA1 20-year benefit of endocrine therapy in premenopausal breast cancer patients by the 70-gene risk signature

Author

LJ Esserman, Christina Yau, Anna Nordenskjöld, Anna L.V. Johansson, Gizeh Pérez-Tenorio, Huma Dar, Tommy Fornander, Olle Stål, L. Van ‘T Veer, Linda S. Lindström, Bo Nordenskjöld, and Christopher C. Benz

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Premenopausal breast cancer, Endocrine therapy, Hematology, business, Gene
Published
2021
Full Text
View/download PDF

2. 6P 25-year survival and benefit from tamoxifen therapy by the clinically used breast cancer markers in lymph node-negative and ER-positive/HER2-negative breast cancer

Author

Tommy Fornander, Anna L.V. Johansson, LJ Esserman, Adina Iftimi, Bo Nordenskjöld, Christopher C. Benz, Christina Yau, Linda S. Lindström, Olle Stål, Gizeh Pérez-Tenorio, Huma Dar, and A. Nordensköljd

Subjects
Oncology, medicine.medical_specialty, Breast cancer, business.industry, Internal medicine, HER2 negative, medicine, Tamoxifen therapy, Hematology, Lymph node negative, medicine.disease, business
Published
2021
Full Text
View/download PDF

3. Increased long-term risk of fatal breast cancer in patients with high intra-tumor heterogeneity of the estrogen receptor – Retrospective analyses of the STO-3 trial

Author

Alexander D. Borowsky, Tommy Fornander, Kamila Czene, Nancy Yiu-Lin Yu, Bo Nordenskjöld, Linda S. Lindström, Laura J. Esserman, Carlie K Thompson, Christopher C. Benz, Olle Stål, and Christina Yau

Subjects
Oncology, medicine.medical_specialty, business.industry, Estrogen receptor, Hematology, medicine.disease, Tumor heterogeneity, Long term risk, Breast cancer, Internal medicine, medicine, In patient, business
Published
2017
Full Text
View/download PDF

4. Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxicity in high-risk breast cancer patients

Author

Tommy Fornander, Jonas Bergh, P-O. Malmström, P-L Kellokumpu-Lehtinen, Bjørn Erikstein, Nils Wilking, N. O. Bengtsson, Gun Anker, H. Bennmarker, and T. Wiklund

Subjects
Oncology, medicine.medical_specialty, Cyclophosphamide, business.industry, medicine.medical_treatment, Hematology, Filgrastim, medicine.disease, Granulocyte colony-stimulating factor, Surgery, Breast cancer, Fluorouracil, Internal medicine, medicine, business, Adjuvant, Radical mastectomy, medicine.drug, Epirubicin
Abstract

Dosage of adjuvant G-CSF (filgrastim)-supported FEC polychemotherapy based on equivalent haematological toxixity in high-risk breast cancer patients

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results